This prompts us to conclude that sGal-9 may be a unique and useful tool for treating Th1/Th17-mediated skin inflammation, including psoriasis, which is probably mediated by the Gal-9-TIM-3 interaction (Niwa et al., 2009). The gene discussed is HAVCR2; the disease is psoriasis.